Tiny Health was founded in 2020 by serial entrepreneur Cheryl Sew Hoy, with co-founder Donald Koo, after her own child's eczema and allergies were traced back to gut imbalances, and she found no infant gut test existed to catch it earlier. That personal origin story is now a company with genuine scientific depth behind it.
Tiny Health runs shotgun metagenomic sequencing, which reads microbial strains and their functions directly, a materially deeper view than the genus-level snapshot most consumer gut tests offer. The tests span pregnancy, postpartum, infancy, childhood, adult gut, and vaginal health, developed with researchers from Johns Hopkins. The company has tested over 100,000 people in three years and has expanded into the EU, Canada, and Mexico.
Tiny Health is attacking a real crisis at the single moment it's most reversible. The moat here is scientific and genuinely hard to copy: proprietary strain-level data, real clinical rigor, and a research posture that most consumer testing brands never attempt, since it's slower and more expensive than shipping a genus-level test and calling it done. That's precisely the kind of domain depth that takes years to build and can't be replicated by a fast-moving competitor in a single funding cycle.
Tiny Health is effectively trying to turn an overlooked biomarker, the infant and family microbiome, into an early warning system for lifelong health, not just a one-time consumer test. Watch whether the company's international expansion into the EU, Canada, and Mexico brings the same research rigor with it, or whether regulatory and reimbursement differences across those markets force a leaner, less research-heavy version of the product abroad.
Pulse Check is a monthly read on what's actually moving across the healthcare startup ecosystem, funding, technology, care delivery, and the categories reshaping how startups compete, without the noise. Every edition is built for founders and operators who don't have time to scan twenty different sources themselves. We track the deals, the industry signal, and the category trends that change what a fundable pitch, a defensible product, or a smart move looks like this month. No filler, no hype, just what matters and why.
Pulse Check is provided for general informational purposes only and does not constitute medical, financial, legal, or investment advice. Nothing in this publication should be relied upon as a substitute for professional advice from a qualified provider, advisor, or practitioner. Collective Loop makes no representations or warranties as to the accuracy, completeness, or currency of any information, data, or figures referenced, and readers should independently verify anything material to their own decisions.
All company names, logos, trademarks, product screenshots, and website imagery referenced or displayed in this publication remain the property of their respective owners. Their inclusion is for editorial and informational purposes only and does not imply endorsement, sponsorship, or affiliation between Collective Loop and the companies featured, unless explicitly stated.
